Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Pomalyst
gptkb:Thalomid |
| gptkbp:activities |
inhibits TNF-alpha production
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associated_with |
gptkb:deep_vein_thrombosis
pulmonary embolism phocomelia |
| gptkbp:caused_by |
birth defects
|
| gptkbp:class |
immunomodulatory drug
|
| gptkbp:clinical_trial |
ongoing for various conditions
|
| gptkbp:composed_of |
can be synthesized from glutamic acid
can be synthesized from phthalimide |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:developed_by |
gptkb:Chemie_Grünenthal
treating insomnia treating morning sickness |
| gptkbp:discovered_by |
gptkb:government_agency
|
| gptkbp:dissolved |
soluble in organic solvents
poorly soluble in water |
| gptkbp:first_introduced |
gptkb:1957
|
| gptkbp:has_impact_on |
quality of life
apoptosis cell differentiation cell growth cognitive function inflammation pain relief anxiety reduction sleep regulation weight gain angiogenesis immune system neuroprotection appetite stimulation fatigue reduction mood stabilization nausea reduction |
| https://www.w3.org/2000/01/rdf-schema#label |
thalidomide
|
| gptkbp:ingredients |
C13 H10 N2 O4 S
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
for side effects
|
| gptkbp:is_used_for |
treating leprosy
treating multiple myeloma |
| gptkbp:market |
gptkb:1961
|
| gptkbp:marketed_as |
gptkb:Thalomid
multiple countries |
| gptkbp:related_to |
gptkb:lenalidomide
gptkb:pomalidomide |
| gptkbp:reunion |
gptkb:healthcare_organization
HIV treatment |
| gptkbp:side_effect |
rash
drowsiness constipation peripheral neuropathy |
| gptkbp:type_of |
50-35-1
|
| gptkbp:used_in |
combination therapy
clinical research |
| gptkbp:weight |
258.33 g/mol
|